Home > Cardiology > No need to adjust rivaroxaban dose for overweight heart disease patients

No need to adjust rivaroxaban dose for overweight heart disease patients

Journal
Journal of the American College of Cardiology
Reuters Health - 02/02/2021 - In overweight or obese heart disease patients, rivaroxaban at standard doses can be added to aspirin to reduce risks of heart attack, stroke or mortality, researchers say. "We demonstrate that the concomitant administration of rivaroxaban (2.5mg twice daily) and aspirin (100mg once daily) is effective across a broad range of body weights without dose adjustment," Dr. Tomasz Guzik of the University of Glasgow, UK, told Reuters Health by email. "This adds critical data to the emerging discussion on the use of...direct oral anticoagulants in obese and overweight patients in other clinical indications." "While this is one step forward, we still need further studies to confirm these results in subjects with very high or very low weights, as these patients were not sufficiently represented in the COMPASS trial population," he acknowledged. "This is important, as nearly 10% of US population is severely obese." As reported in the Journal...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on